Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb
Sometimes, the largest and the stablest businesses are excellent options to anchor your portfolio with some steady cash flow. In particular, GlaxoSmithKline (NYSE: GSK) and Bristol-Myers Squibb (NYSE: BMY) are two of the world's most preeminent pharmaceutical companies, but neither has consistently outperformed the market over the past five years.
Still, both companies pay a decent dividend, and they aren't going to go out of business anytime soon due to their massive portfolios of approved medicines and candidates in development. Let's examine each company to see if one of them offers better long-term prospects for your portfolio than the other.
Image source: Getty Images.
Source Fool.com
